ArticleMolecular neurobiology2025
GPR30 Inhibits Neuronal Apoptosis After Subarachnoid Hemorrhage by Activating the Wnt/β-Catenin Pathway in a m6A-dependent Manner.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Neuronal apoptosis is associated with early brain injury after subarachnoid hemorrhage (SAH). In this study, the regulatory effects of GPR30 on neuronal apoptosis after SAH, METTL14 expression, and the Wnt/β-catenin pathway were investigated. SAH models were constructed in vitro in neurons and in vivo in rats. We found that the GPR30 protein was downregulated in OxyHB-stimulated neurons and SAH rat brain tissue. The GPR30 agonist G1 decreased iNOS levels and apoptosis in OxyHB-stimulated neurons. G1 increased m6A levels in OxyHB-stimulated neurons, increased the expression of METTL14 and Bcl-2, and reduced Caspase-3 and Bax levels. The GPR30 inhibitor G15 had the opposite effect as G1. METTL14 overexpression increased m6A levels in OxyHB-stimulated neurons; increased the expression of METTL14, Wnt1, β-catenin, and Bcl-2; decreased Caspase-3 and Bax levels; and inhibited apoptosis. The Wnt inhibitor IWR-1 abrogated the effects of METTL14 overexpression in OxyHB-stimulated neurons. In vivo, the results revealed that G1 decreased the mNSS, cerebral edema score, and caspase-3, IL-6, IL-1β, Bax, and p-β-catenin expression; inhibited apoptosis and nitric oxide production; and increased GPR30, IFN-γ, TGF-β1, METTL14, Wnt1, and β-catenin expression. G15 had the opposite effect of G1. METTL14 knockdown abrogated the effects of G1 in SAH model rats. Our results suggest that GPR30 inhibits neuronal apoptosis after SAH via Wnt/β-catenin pathway regulation and METTL14-mediated m6A modification, providing a new therapeutic target for SAH.
Indexed as
Identifiers
40131697What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.